{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:47:53Z","timestamp":1790246873321,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ctrv.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,4,22]],"date-time":"2018-04-22T17:56:20Z","timestamp":1524419780000},"page":"64-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Management of treatment-related toxicities in advanced medullary thyroid cancer"],"prefix":"10.1016","volume":"66","author":[{"given":"Marcia S.","family":"Brose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith C.","family":"Bible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Q.M.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Worden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2018.04.007_b0005","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Thyroid Carcinoma, V2.2017. \u00a9 National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed June 16, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK\u00ae, NCCN\u00ae, NCCN GUIDELINES\u00ae, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network Inc."},{"issue":"6","key":"10.1016\/j.ctrv.2018.04.007_b0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"American thyroid association guidelines task force on medullary thyroid carcinoma. Revised american thyroid association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"Supp 1","key":"10.1016\/j.ctrv.2018.04.007_b0015","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1756-6614-6-S1-S7","article-title":"Treatment of advanced medullary thyroid cancer","volume":"6","author":"Smit","year":"2013","journal-title":"Thyroid Res"},{"issue":"1","key":"10.1016\/j.ctrv.2018.04.007_b0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.surg.2016.04.053","article-title":"Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years","volume":"161","author":"Randle","year":"2017","journal-title":"Surgery"},{"issue":"10","key":"10.1016\/j.ctrv.2018.04.007_b0025","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1634\/theoncologist.2013-0053","article-title":"Current understanding and management of medullary thyroid cancer","volume":"18","author":"Roy","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2018.04.007_b0030","unstructured":"CAPRELSA\u00ae (vandetanib) tablets for oral use [prescribing information]. Cambridge, MA: Sanofi Genzyme; 2016."},{"key":"10.1016\/j.ctrv.2018.04.007_b0035","unstructured":"COMETRIQ\u00ae (cabozantinib) capsules, for oral use [prescribing information]. South San Francisco, CA: Exelixis, Inc.; 2016."},{"issue":"29","key":"10.1016\/j.ctrv.2018.04.007_b0040","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2018.04.007_b0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2018.04.007_b0050","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2018.04.007_b0055","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.01.001","article-title":"Management of sorafenib-related adverse events: a clinician's perspective","volume":"41","author":"Brose","year":"2014","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2018.04.007_b0060","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdi247","article-title":"Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors","volume":"16","author":"Holden","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.04.007_b0065","unstructured":"ClinicalTrials.gov. To compare the effects of two doses of vandetanib in patients with advanced medullary thyroid cancer. ClinicalTrials.gov Identifier: NCT01496313, https:\/\/clinicaltrials.gov\/ [accessed 06.16.17]."},{"issue":"29","key":"10.1016\/j.ctrv.2018.04.007_b0070","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2013.51.5098","article-title":"How to incorporate new tyrosine kinase inhibitors in the treatment of patients with medullary thyroid cancer","volume":"31","author":"Haddad","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.007_b0075","unstructured":"ClinicalTrials.gov. A study of two different doses of cabozantinib (XL184) in progressive, metastatic medullary thyroid cancer (EXAMINER). ClinicalTrials.gov Identifier: NCT01896479, https:\/\/clinicaltrials.gov\/ [accessed 06.16.17]."},{"issue":"8","key":"10.1016\/j.ctrv.2018.04.007_b0080","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","article-title":"Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors","volume":"18","author":"Lenihan","year":"2013","journal-title":"Oncologist"},{"key":"#cr-split#-10.1016\/j.ctrv.2018.04.007_b0085.1","unstructured":"CAPRELSA?? REMS program. Risk evaluation and mitigation strategy. Welcome to the CAPRELSA REMS program, http:\/\/www.caprelsarems.com;"},{"key":"#cr-split#-10.1016\/j.ctrv.2018.04.007_b0085.2","unstructured":"December 2013 [accessed 06.16.17]."},{"issue":"15","key":"10.1016\/j.ctrv.2018.04.007_b0090","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2018.04.007_b0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3322\/caac.21184","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.ctrv.2018.04.007_b0100","first-page":"3621","article-title":"A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients","volume":"2016","author":"Huo","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"14","key":"10.1016\/j.ctrv.2018.04.007_b0105","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended guidelines for the treatment of cancer treatment-induced diarrhea","volume":"22","author":"Benson","year":"2004","journal-title":"J Clin Oncol"},{"key":"#cr-split#-10.1016\/j.ctrv.2018.04.007_b0110.1","unstructured":"National Cancer Institute. Gastrointestinal complications (PDQ??)-health professional version. Diarrhea. https:\/\/www.cancer.gov\/about-cancer\/treatment\/side-effects\/constipation\/GI-complications-hp-pdq#section\/_119;"},{"key":"#cr-split#-10.1016\/j.ctrv.2018.04.007_b0110.2","unstructured":"May 2017 [accessed 06.16.17]."},{"key":"10.1016\/j.ctrv.2018.04.007_b0115","unstructured":"IMODIUM\u00ae (loperamide hydrochloride) [prescribing information]. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division; October 2016."},{"key":"10.1016\/j.ctrv.2018.04.007_b0120","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Cancer-Related Fatigue, V2.2017. \u00a9 National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed June 16, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK\u00ae, NCCN\u00ae, NCCN GUIDELINES\u00ae, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network Inc."},{"issue":"2","key":"10.1016\/j.ctrv.2018.04.007_b0125","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1634\/theoncologist.2009-0303","article-title":"Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU","volume":"15","author":"Ravaud","year":"2010","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ctrv.2018.04.007_b0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/ERC-11-0351","article-title":"Sorafenib in metastatic thyroid cancer","volume":"19","author":"Capdevila","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2018.04.007_b0135","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/jc.2013-3713","article-title":"Endocrine malignancies disease oriented group, mayo clinic cancer center, and the mayo Phase 2 Consortium. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H","volume":"99","author":"Bible","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ctrv.2018.04.007_b0140","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.ejca.2015.05.020","article-title":"An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer","volume":"51","author":"Lim","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2018.04.007_b0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2018.04.007_b0150","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3109\/0284186X.2016.1157264","article-title":"Combination chemotherapy with 5-fluorouracil and dacarbazine in advanced medullary thyroid cancer, a possible alternative?","volume":"55","author":"Marchand","year":"2016","journal-title":"Acta Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2018.04.007_b0155","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0031-1279704","article-title":"Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: a single-center experience","volume":"119","author":"Deutschbein","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"10.1016\/j.ctrv.2018.04.007_b0160","first-page":"983","article-title":"Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma","volume":"85","author":"Vitale","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2018.04.007_b0165","unstructured":"ClinicalTrials.gov. Trial of LBH589 in metastatic thyroid cancer. ClinicalTrials.gov Identifier: NCT01013597, https:\/\/clinicaltrials.gov\/. [accessed 06.16.17]."},{"key":"10.1016\/j.ctrv.2018.04.007_b0170","unstructured":"ClinicalTrials.gov. Personalized cancer therapy for patients with metastatic medullary thyroid cancer. ClinicalTrials.gov Identifier: NCT02363647, https:\/\/clinicaltrials.gov\/. [accessed 01.19.17]."},{"key":"10.1016\/j.ctrv.2018.04.007_b0175","unstructured":"ClinicalTrials.gov. Phase II study of tipifarnib in squamous head and neck cancer with HRAS mutations. ClinicalTrials.gov Identifier: NCT02383927, https:\/\/clinicaltrials.gov\/. [accessed 06.16.17]."},{"key":"10.1016\/j.ctrv.2018.04.007_b0180","unstructured":"ClinicalTrials.gov. GI6207 for advanced medullary thyroid cancer. ClinicalTrials.gov Identifier: NCT01856920, https:\/\/clinicaltrials.gov\/ [accessed 06.16.17]."},{"key":"10.1016\/j.ctrv.2018.04.007_b0185","unstructured":"ClinicalTrials.gov. Study of pembrolizumab (MK3475) in participants with advanced solid tumors (MK3475158\/KEYNOTE158). ClinicalTrials.gov Identifier: NCT02628067, https:\/\/clinicaltrials.gov\/ [accessed 06.16.17]."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:20:11Z","timestamp":1604190011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737218300513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":39,"alternative-id":["S0305737218300513"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.04.007","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of treatment-related toxicities in advanced medullary thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}